Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank29
Studio
Year-over-Year Change

Cash generated from core business operations

Percentile
P29
Within normal range
vs 5Y Ago
-2.7x
Contraction
Streak
2 yr
Consecutive growthContracting
PeriodValueYoY Change
2025$-19.27M+75.5%
2024$-78.76M+23.6%
2023$-103.15M-21.7%
2022$-84.78M-21.1%
2021$-70.00M-1087.5%
2020$7.09M-90.1%
2019$71.42M+144.4%
2018$29.22M-44.5%
2017$52.65M+47.0%
2016$35.81M-